Capecitabine with cyclophophamide as maintenance therapy in advanced colorectal cancer patients
收藏NIAID Data Ecosystem2026-03-13 收录
官方服务：
资源简介：
Primary outcome(s): In phase I the OBD of capecitabine would be identified using response assessment criteria RECIST version 1.1 and flow cytometry measurement of CEC. So, a twin primary endpoints of clinical benefit rate at 2 months ( CR or PR or SD persisting till 2 months) and proportional decline in CEC will be used for determination of OBD. Timepoint: 30 months
创建时间：
2022-01-15
